J 2022

Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance

FARSA, Oldřich, Veronika BALLAYOVÁ, Radka ŽÁČKOVÁ, Peter KOLLÁR, Tereza KAUEROVÁ et. al.

Základní údaje

Originální název

Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance

Autoři

FARSA, Oldřich (203 Česká republika, domácí), Veronika BALLAYOVÁ (703 Slovensko, garant, domácí), Radka ŽÁČKOVÁ (203 Česká republika, domácí), Peter KOLLÁR (203 Česká republika, domácí), Tereza KAUEROVÁ (203 Česká republika, domácí) a Peter ZUBÁČ (703 Slovensko, domácí)

Vydání

International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2022, 1422-0067

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.600

Kód RIV

RIV/00216224:14160/22:00126601

Organizační jednotka

Farmaceutická fakulta

UT WoS

000851097400001

Klíčová slova anglicky

aminopeptidase N; acetamidophenones; Schiff bases; semicarbazones; thiosemicarbazones; inhibition of proliferation

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 1. 2. 2023 13:58, JUDr. Sabina Krejčiříková

Anotace

V originále

Aminopeptidase N (APN), also known as CD13 antigen or membrane alanyl aminopeptidase, belongs to the M1 family of the MA clan of zinc metallopeptidases. In cancer cells, the inhibition of aminopeptidases including APN causes the phenomenon termed the amino acid deprivation response (AADR), a stress response characterized by the upregulation of amino acid transporters and synthetic enzymes and activation of stress-related pathways such as nuclear factor kB (NFkB) and other pro-apoptotic regulators, which leads to cancer cell death by apoptosis. Recently, APN inhibition has been shown to augment DR4-induced tumor cell death and thus overcome resistance to cancer treatment with DR4-ligand TRAIL, which is available as a recombinant soluble form dulanermin. This implies that APN inhibitors could serve as potential weapons for overcoming cancer treatment resistance. In this study, a series of basically substituted acetamidophenones and the semicarbazones and thiosemicarbazones derived from them were prepared, for which APN inhibitory activity was determined. In addition, a selective anti-proliferative activity against cancer cells expressing APN was demonstrated. Our semicarbazones and thiosemicarbazones are the first compounds of these structural types of Schiff bases that were reported to inhibit not only a zinc-dependent aminopeptidase of the M1 family but also a metalloenzyme.

Návaznosti

MUNI/A/1682/2020, interní kód MU
Název: Návrh, syntéza a hodnocení derivátů skupin léčiv s inhibiční enzymatickou aktivitou
Investor: Masarykova univerzita, Návrh, syntéza a hodnocení derivátů skupin léčiv s inhibiční enzymatickou aktivitou
MUNI/IGA/0932/2021, interní kód MU
Název: Basic ketones and their derivatives as potential anti-infective and anti-tumor drugs
Investor: Masarykova univerzita, Basic ketones and their derivatives as potential anti-infective and anti-tumor drugs